The NOVAMag® membrane is a medical device approved in the EU, and is a completely resorbable and biodegradable metal membrane. This medical device is used in the treatment of bone defects in the oral cavity. The membrane ensures sufficient stability of the bone augmentation material and provides a barrier to the soft tissue. This enables new bone to form in the defect space and for the subsequent placement of dental implants. In this clinical trial, the NOVAMag® membrane is compared with the Jason® collagen membrane, another medical device for supporting bone regeneration, with the aim of demonstrating the non-inferiority in terms of radiographically measured volumetric bone gain of the NOVAMag® membrane to the comparator membrane.
GBR is a well-established surgical procedure based on the use of tissue barriers to separate the void of hard tissue defects from overlying connective tissues, thus preventing the ingrowth of soft tissue into the defect site resulting in improved bone regeneration. GBR is used both with and without different bone graft materials, such as allografts, xenografts and synthetic substitute materials, which have shown comparable results to those obtained with autologous bone in localized horizontal defects. The barrier membranes used in GBR can be produced from animal (bovine, porcine), human (allogenic) and synthetic biomaterials. Due to their origin, composition and manufacturing process, each biomaterial performs differently in the human body, with their own associated advantages and disadvantages. Non-resorbable membranes (primarily made from PTFE \[polytetrafluoroethylene\] and titanium\] can offer mechanical reinforcement to protect the defect void, as well as maintain a continuous barrier function until they are removed. The main disadvantage of these membranes is the necessity of a second surgical procedure for their removal. In response to this disadvantage, resorbable membranes have been developed with porcine collagen membranes considering the standard product for use in GBR. These collagen membranes produce excellent biocompatible results, but they lack mechanical stability, especially for use in larger augmentation sites. To address the aforementioned issues of both the resorbable and non-resorbable membranes, botiss biomaterials GmbH has developed the NOVAMag® membrane, which has recently received CE approval. The NOVAMag® membrane is a resorbable, biodegradable magnesium membrane. The material properties of the pure magnesium membrane culminate into a design that has a mechanical stability not provided by other resorbable membranes. Despite being resorbable, the membrane maintains a separation of the soft and hard tissues until the bony defect has been repaired (data on file at botiss). The ability of membranes to resist collapse into the defect void and maintain space for the ingrowth of new bone is viewed as an important aspect for producing a successful regenerative outcome. This is most easily achieved by using a strong material that can resist the external pressures of the overlying soft tissue and the forces experienced during function. The risk of collapse tends to be higher for resorbable membranes due to inferior mechanical properties. Mechanical testing performed by botiss have proven that the magnesium membrane is self-supporting and substantially stronger than other resorbable collagen membranes. Therefore, the risk of collapse into the defect void, as reported for collagen membranes, could potentially be prevented by using the NOVAMag® membrane. The aim of this randomized clinical study is to compare a bioresorbable magnesium NOVAMag® membrane with the collagen Jason® membrane in patients requiring guided bone regeneration.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
84
After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured
After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration
Medical University of Graz Department of Dental Medicine and Oral Health
Graz, Austria
RECRUITINGUniversity of Vienna, Department of Oral Surgery
Vienna, Austria
RECRUITINGCopenhagen University Hospital, Department of Oral & Maxillofacial Surgery
Copenhagen, Denmark
RECRUITINGStudio medico odontoiatrico Papi Stp Srl
Roma, Italy
RECRUITINGStudio Tabanella
Roma, Italy
RECRUITINGRelative difference in bone volume between the groups at the augmentation site after GBR measured radiographically
Mean volumetric increase in %
Time frame: Pre-treatment visit (T-1) to the clinical check up visit after five and a half months (T4)
Histomorphometric assessment of the differences in bone volume between the groups
After 6 months a biopsy is taken from the site of dental implant insertion for further analysis. Undecalcified thin ground sections will be prepared. The following variables will be determined: * Bone volume per tissue volume in % (BV/TV) * New bone volume per tissue volume in % (nBV/TV) * Old bone volume per tissue volume in % (oBV/TV) * Total graft volume per tissue volume in % (GV/TV)
Time frame: T5: after a healing period of 6 months
Evaluation of between group differences for the presence of side effects
Presence or absence of side effects will be evaluated by the investigator during the scheduled follow-up appointments. Side effects to be assessed are: * Gas formation * Prickly feeling at surgery site (dysesthesia) * Redness/swelling * Bleeding * Wound dehiscence * Infection * Abscess/pus formation
Time frame: At each follow-up visit: T1 (after 7-10 days), T2 (after 14 ± 3 days), T3 (after 1 month ± 4 days) and T5 (after 6 months ± 2 weeks)
Evaluation of between group differences for pain
Pain will be self-assessed by the patients via a numerical rating scale (NRS) during the scheduled follow-up appointments. The scale has a measurement range of 0 to 10 (each inclusive). The higher the value, the more pain the patients experience.
Time frame: At each follow-up visit: T1 (after 7-10 days), T2 (after 14 ± 3 days), T3 (after 1 month ± 4 days) and T5 (after 6 months ± 2 weeks)
Safety outcome measures
The following Safety Endpoints will be evaluated by group at each visit: * Adverse events (AE) and Serious adverse events (SAEs) * Device related adverse events (adverse device effects (ADE) * Seriousness of device related adverse events (serious adverse device effect (SADE) * Device deficiency (DD)
Time frame: At T-1 (pre-treatment), T0 (= day 0 = day of surgery), T1 (after 7-10 days), T2 (after 14 ± 3 days), T3 (after 1 month ± 4 days), T5 (after 6 months ± 2 weeks), T6 (7-10 days after T5)
Usability of the NOVAMag® membrane and its accessory products
By completing a survey regarding the handling of the NOVAMag® membrane and its accessories by the investigator the usability will be evaluated.
Time frame: At the end of the visit T0 [= day 0 = directly after GBR surgery]
Radiographic outcome measure: Changes in horizontal bone dimensions over time in mm.
At T-1 and T4 a Cone Beam Computed Tomography (CBCT) is taken. CBCTs are compared and horizontal bone dimensions are measured at 2 mm, 4 mm, and 6 mm from the crest.
Time frame: At T-1 (pre-treatment) and T4 (5 and a half months ± 2 weeks)
Radiographic outcome measure: Changes in vertical bone dimensions over time in mm.
At T-1 and T4 a Cone Beam Computed Tomography (CBCT) is taken. CBCTs are compared and vertical bone dimensions are measured in mm.
Time frame: At T-1 (pre-treatment) and T4 (5 and a half months ± 2 weeks)
Radiographic outcome measure: Bone quality assessment
Bone quality assessment by evaluation of presence or absence of gas cavities by analysis of CBCT images after 6 months (only presence is reported from X-rays)
Time frame: T4 (after 5 and a half months ± 2 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.